Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
China · Delayed Price · Currency is CNY 62.59
-0.01 (-0.02%)
Sep 11, 2026, 3:04 PM CST
SHE:002653 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 69,429 | 56,927 | 36,883 | 25,545 | 23,695 | 21,747 | |
Market Cap Growth | 8.51% | 54.35% | 44.38% | 7.81% | 8.96% | 16.68% |
Enterprise Value | 69,711 | 57,841 | 37,658 | 26,256 | 25,227 | 22,521 |
Last Close Price | 62.59 | 50.66 | 32.58 | 22.43 | 21.56 | 19.54 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 74.40 | 219.31 | 93.27 | 86.56 | 85.52 | 63.02 |
Forward PE | 68.28 | 91.92 | 58.20 | 62.99 | 69.53 | 62.77 |
PS Ratio | 12.66 | 12.97 | 9.91 | 7.61 | 7.86 | 7.84 |
PB Ratio | 14.42 | 13.28 | 8.78 | 6.13 | 7.56 | 7.45 |
P/TBV Ratio | 25.12 | 20.53 | 12.56 | 7.45 | 10.18 | 10.07 |
P/FCF Ratio | 75.93 | 125.38 | 26513.18 | 436.15 | - | - |
P/OCF Ratio | 58.00 | 72.43 | 83.44 | 56.82 | 250.62 | 607.43 |
PEG Ratio | - | 1.18 | 1.18 | 0.87 | 0.87 | 0.87 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 12.72 | 13.18 | 10.12 | 7.83 | 8.37 | 8.12 |
EV/EBITDA Ratio | 61.25 | 125.08 | 75.01 | 48.24 | 79.50 | 122.44 |
EV/EBIT Ratio | 83.74 | 289.76 | 143.72 | 79.19 | 178.20 | 598.98 |
EV/FCF Ratio | 76.24 | 127.40 | 27070.47 | 448.29 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.47 | 0.46 | 0.46 | 0.43 | 0.67 | 0.43 |
Debt / EBITDA Ratio | 1.99 | 4.18 | 3.74 | 3.28 | 6.48 | 6.55 |
Debt / FCF Ratio | 2.48 | 4.36 | 1373.28 | 30.84 | - | - |
Net Debt / Equity Ratio | 0.06 | 0.14 | 0.17 | 0.12 | 0.43 | 0.23 |
Net Debt / EBITDA Ratio | 0.25 | 1.28 | 1.40 | 0.88 | 4.21 | 3.67 |
Net Debt / FCF Ratio | 0.31 | 1.31 | 506.23 | 8.16 | -2.21 | -1.01 |
Asset Turnover | 0.74 | 0.64 | 0.55 | 0.53 | 0.55 | 0.56 |
Inventory Turnover | 4.11 | 4.38 | 3.84 | 3.10 | 3.05 | 3.91 |
Quick Ratio | 1.35 | 1.56 | 1.48 | 1.50 | 1.09 | 0.81 |
Current Ratio | 1.53 | 1.81 | 1.74 | 1.76 | 1.38 | 1.02 |
Return on Equity (ROE) | 21.39% | 6.12% | 11.14% | 8.09% | 12.94% | 17.93% |
Return on Assets (ROA) | 7.00% | 1.81% | 2.44% | 3.26% | 1.60% | 0.47% |
Return on Invested Capital (ROIC) | 15.98% | 3.87% | 5.49% | 7.11% | 3.51% | 1.20% |
Return on Capital Employed (ROCE) | 14.80% | 3.70% | 5.00% | 6.40% | 3.10% | 1.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | 1.37% | 0.46% | 1.07% | 1.16% | 1.17% | 1.59% |
FCF Yield | 1.32% | 0.80% | 0.00% | 0.23% | -2.56% | -3.07% |
Dividend Yield | 0.79% | 0.53% | 1.27% | 0.89% | - | 0.95% |
Payout Ratio | 34.35% | 128.34% | 106.72% | 14.43% | 89.32% | 123.52% |
Buyback Yield / Dilution | 1.09% | 0.11% | -3.37% | -2.57% | 1.17% | 0.07% |
Total Shareholder Return | 1.88% | 0.64% | -2.10% | -1.67% | 1.17% | 1.01% |